EA201992410A2 - TROPOMYOSIN-DEPENDENT KINASE INHIBITORS (Trk) - Google Patents

TROPOMYOSIN-DEPENDENT KINASE INHIBITORS (Trk)

Info

Publication number
EA201992410A2
EA201992410A2 EA201992410A EA201992410A EA201992410A2 EA 201992410 A2 EA201992410 A2 EA 201992410A2 EA 201992410 A EA201992410 A EA 201992410A EA 201992410 A EA201992410 A EA 201992410A EA 201992410 A2 EA201992410 A2 EA 201992410A2
Authority
EA
Eurasian Patent Office
Prior art keywords
tropomyosin
dependent kinase
trk
inhibitors
trk inhibitors
Prior art date
Application number
EA201992410A
Other languages
Russian (ru)
Other versions
EA201992410A3 (en
Inventor
Джон Л. мл. Кейн
Глория Мэттьюз
Маркус Метц
Михаэль Коте
Цзиньюй Лю
Эндрю Сколт
Original Assignee
Джензим Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джензим Корпорейшн filed Critical Джензим Корпорейшн
Publication of EA201992410A2 publication Critical patent/EA201992410A2/en
Publication of EA201992410A3 publication Critical patent/EA201992410A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/50—Organo-phosphines

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Ингибиторы тропомиозин-зависимых киназ (Trk-ингибиторы) являются соединениями-малыми молекулами, пригодными в лечении заболевания. Trk-ингибиторы можно применять в качестве фармацевтических средств и в фармацевтических композициях. Trk-ингибиторы пригодны в лечении воспалительных заболеваний, аутоиммунного заболевания, нарушений метаболизма в костной ткани и/или рака и особенно пригодны в лечении остеоартрита (OA), боли и связанной с OA боли. Trk-ингибиторы также пригодны для ингибирования тропомиозин-зависимой киназы A (TrkA), тропомиозин-зависимой киназы B (TrkB), тропомиозин-зависимой киназы C (TrkC) и/или c-FMS (клеточного рецептора для колониестимулирующего фактора-1 (CSF-1)).Tropomyosin-dependent kinase inhibitors (Trk inhibitors) are small molecule compounds useful in treating a disease. Trk inhibitors can be used as pharmaceuticals and in pharmaceutical compositions. Trk inhibitors are useful in the treatment of inflammatory diseases, autoimmune diseases, metabolic disorders in bone tissue and / or cancer, and are particularly useful in the treatment of osteoarthritis (OA), pain and OA-related pain. Trk inhibitors are also suitable for inhibiting tropomyosin-dependent kinase A (TrkA), tropomyosin-dependent kinase B (TrkB), tropomyosin-dependent kinase C (TrkC) and / or c-FMS (cell receptor for colony stimulating factor-1 (CSF- 1)).

EA201992410A 2014-08-22 2014-12-10 TROPOMYOSIN-DEPENDENT KINASE (TRK) INHIBITORS EA201992410A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462040750P 2014-08-22 2014-08-22

Publications (2)

Publication Number Publication Date
EA201992410A2 true EA201992410A2 (en) 2020-02-28
EA201992410A3 EA201992410A3 (en) 2020-05-31

Family

ID=69636691

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992410A EA201992410A3 (en) 2014-08-22 2014-12-10 TROPOMYOSIN-DEPENDENT KINASE (TRK) INHIBITORS

Country Status (1)

Country Link
EA (1) EA201992410A3 (en)

Also Published As

Publication number Publication date
EA201992410A3 (en) 2020-05-31

Similar Documents

Publication Publication Date Title
EA201691196A1 (en) TROPOMYOSIN-DEPENDENT KINAZ INHIBITORS (TRK)
EA201991399A1 (en) AMINOTRIAZOLOPYRIDINE COMPOUNDS AND THEIR APPLICATION IN TREATMENT OF CANCER
EA201890725A1 (en) PHARNESIDE X-RECEPTOR AGONISTS AND THEIR APPLICATION
SA518391624B1 (en) Modulators of ROR-GAMMA
EA201691151A1 (en) CONNECTIONS FOR THE TREATMENT OF PATIENTS WITH ROS1-MUTANT CANCER CELLS
EA201790492A1 (en) CONNECTIONS THAT INHIBIT McL-1 PROTEIN
EA201792047A1 (en) NEW CONNECTIONS
EA201791018A1 (en) DERIVATIVES OF 6-AMINO-7-BICYCLO-7-DEAZAPURIN AS PROTECTINININASE INHIBITORS
EA201691516A1 (en) DIHYDROPYRROLOPIRIDINOVYY INHIBITORS ROR-GAMMA
EA201790078A1 (en) MNK INHIBITORS AND RELATED METHODS
EA201390772A1 (en) NEW SALTS AND POLYMORPHIC FORMS OF AFATINIBA
EA201391682A1 (en) SUBSTITUTED DERIVATIVES OF INDAZOLS ACTIVE AS KINASE INHIBITORS
EA201691940A1 (en) NEW CONNECTIONS
EA201590855A1 (en) COMPOUNDS OF PYRROPOLYMIDININE AS KINAZ INHIBITORS
EA201500394A1 (en) INHIBITORS DISTEMYLASE HYSTONES
EA201792304A1 (en) COMBINED THERAPY FOR CANCER TREATMENT
EA201290103A1 (en) HETEROCYCLIC COMPOUNDS AND THEIR USE
EA201891399A1 (en) BIPIRAZOLE DERIVATIVES, SUITABLE FOR THE TREATMENT OF AUTOIMMUNE DISEASES
EA201201661A1 (en) NEW AMINOPYRAZOLOHINAZOLINES
EA201790519A1 (en) THERAPEUTIC CONNECTIONS AS INTEGRATORS OF OREXIN-1 RECEPTOR
JOP20200230A1 (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EA202190588A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA202191478A1 (en) HETEROAROMATIC COMPOUNDS AS VANIN INHIBITORS
EA201891710A1 (en) THERAPEUTIC CONNECTIONS
EA201790253A1 (en) ALDOSTERONSYNTASE INHIBITORS